Goldman Sachs Group Inc. Grows Position in GeneDx Holdings Corp. $WGS

Goldman Sachs Group Inc. grew its stake in shares of GeneDx Holdings Corp. (NASDAQ:WGS) by 4.5% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 1,220,502 shares of the company’s stock after acquiring an additional 52,322 shares during the quarter. Goldman Sachs Group Inc.’s holdings in GeneDx were worth $158,738,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of WGS. Royal Bank of Canada increased its position in GeneDx by 30.2% during the first quarter. Royal Bank of Canada now owns 29,479 shares of the company’s stock worth $2,611,000 after buying an additional 6,840 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of GeneDx by 6.3% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,641 shares of the company’s stock valued at $677,000 after purchasing an additional 453 shares during the period. NewEdge Advisors LLC grew its position in shares of GeneDx by 270,700.0% in the first quarter. NewEdge Advisors LLC now owns 2,708 shares of the company’s stock valued at $240,000 after purchasing an additional 2,707 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of GeneDx by 67.5% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 28,224 shares of the company’s stock valued at $2,500,000 after purchasing an additional 11,375 shares during the period. Finally, Cetera Investment Advisers purchased a new stake in shares of GeneDx in the second quarter valued at $249,000. Hedge funds and other institutional investors own 61.72% of the company’s stock.

Key GeneDx News

Here are the key news stories impacting GeneDx this week:

• Negative Sentiment: A federal securities class action has been filed alleging GeneDx made false and misleading statements, including claims tied to its Fabric Genomics acquisition and its impact on the company’s business and prospects. Article Title
• Negative Sentiment: Multiple law firms are now soliciting investors and advertising lead-plaintiff deadlines, signaling rising legal overhang and potential additional distraction/costs for the company. Article Title
• Neutral Sentiment: Several firms are reminding investors that the deadline to seek lead-plaintiff status in the GeneDx class action is August 3, 2026; this is mainly procedural but keeps the controversy in focus. Article Title
• Neutral Sentiment: Commentary from plaintiff firms continues to highlight the prior Q1 2026 earnings miss, the steep stock drop, and the guidance cut as evidence supporting the lawsuit, reinforcing already negative investor sentiment. Article Title
• Negative Sentiment: The lawsuit and related notices may keep investors focused on GeneDx’s earlier operational disappointment, including the revenue miss and widened losses, which remain a headwind for the stock. Article Title

Wall Street Analyst Weigh In

A number of brokerages have recently commented on WGS. BTIG Research lowered their price objective on GeneDx from $170.00 to $90.00 and set a “buy” rating for the company in a research report on Tuesday, May 5th. Wall Street Zen downgraded GeneDx from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Jefferies Financial Group set a $150.00 price objective on GeneDx in a research report on Monday, February 23rd. Piper Sandler reaffirmed an “overweight” rating and issued a $130.00 price objective (down from $160.00) on shares of GeneDx in a research report on Tuesday, February 24th. Finally, Zacks Research downgraded GeneDx from a “strong-buy” rating to a “hold” rating in a research report on Friday, April 24th. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, GeneDx has a consensus rating of “Moderate Buy” and a consensus price target of $96.43.

Insider Buying and Selling at GeneDx

In related news, Director Casdin Capital, Llc acquired 140,000 shares of GeneDx stock in a transaction on Wednesday, May 20th. The shares were bought at an average price of $43.81 per share, for a total transaction of $6,133,400.00. Following the completion of the purchase, the director directly owned 3,507,164 shares in the company, valued at $153,648,854.84. This trade represents a 4.16% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Kevin Feeley sold 392 shares of the business’s stock in a transaction dated Wednesday, April 29th. The stock was sold at an average price of $65.19, for a total value of $25,554.48. Following the transaction, the chief financial officer owned 34,942 shares in the company, valued at approximately $2,277,868.98. This represents a 1.11% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders bought 2,056,420 shares of company stock valued at $82,035,340 and sold 72,382 shares valued at $4,889,473. 29.60% of the stock is owned by company insiders.

GeneDx Price Performance

WGS stock opened at $52.21 on Monday. The stock has a 50-day moving average price of $55.44 and a two-hundred day moving average price of $92.65. GeneDx Holdings Corp. has a 12-month low of $32.21 and a 12-month high of $170.87. The company has a current ratio of 3.09, a quick ratio of 2.95 and a debt-to-equity ratio of 0.38. The company has a market cap of $1.55 billion, a PE ratio of -19.48 and a beta of 1.96.

GeneDx (NASDAQ:WGS) last posted its quarterly earnings results on Monday, May 4th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.22). GeneDx had a negative net margin of 17.58% and a positive return on equity of 9.15%. The firm had revenue of $102.25 million for the quarter, compared to analysts’ expectations of $112.46 million. During the same period last year, the firm posted ($0.23) EPS. As a group, research analysts predict that GeneDx Holdings Corp. will post -1 EPS for the current year.

GeneDx Company Profile

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.